<DOC>
	<DOCNO>NCT01803945</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multiple-ascending dose study orally administer AVE8112 patient Parkinson 's Disease ( PD ) .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study Assess Safety , Tolerability , Pharmacokinetics , Pharmacodynamics AVE8112 Patients With Parkinson 's Disease</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multiple-ascending dose study orally administer AVE8112 patient Parkinson 's Disease ( PD ) . Sequential cohort eight patient PD administer ascend oral dos AVE8112 ( n=6 ) placebo ( n=2 ) day 14 day . Dosing subsequent cohort proceed , dose level select , safety tolerability previous cohort review . Doses plan 1.0 , 2.0 , 3.0 , 4.0 mg day 14 day . These planned treatment , dos may modify base safety review previous cohort ( ) . In addition , cohort may add reconfirm previously administer dose , and/or titration strategy may employ reach desire dose . Patients assess clinic 30 hour follow initial oral dose AVE8112 placebo . Subsequent dose occur outpatient basis . Patients receive telephone call Days 3 10 monitor adverse event ( AEs ) concomitant medication , also assess clinic Study Days 7 ( outpatient ) , 14 ( outpatient ) , 28 ( ± 3 day ) ( Follow-up visit ) . Safety assessment include physical examination , vital sign , ECGs , clinical laboratory evaluation , Movement Disorder Society Unified Parkinson 's Disease Rating Scale ( MDS-UPDRS ) , Columbia Suicide Severity Rating Scale ( C-SSRS ) . Pharmacodynamic assessment include Parkinson 's Disease Cognitive Rating Scale ( PD-CRS ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Aged 35 70 , inclusive , diagnosis PD , currently treat stable regimen ( least 4 week ) antiparkinsonian drug include least one L 3,4 dihydroxyphenylalanine ( L DOPA ) contain therapy without dopamine agonist Screening . Patients must least two follow : rest tremor , bradykinesia , rigidity ( must either rest tremor bradykinesia ) , gait disturbance assess physical/neurological exam Screening visit . A diagnosis PD 10 year less Screening . Hoehn Yahr stage I III . Male female age 30 year old time PD diagnosis . Body Mass Index ( BMI ) approximately ≥18 ≤32 kg/m2 ; total body weight &gt; 50 kg ( l10 lb ) . Female patient must nonchildbearing potential . Clinically significant history evidence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological , immunological , psychiatric disorder ( ) determine Investigator designee . Female patient breastfeed female patient positive serum pregnancy test . Use cholinergic medication cholinergic effect . History orthostatic hypotension symptomatic drop SBP . Any subject advance Parkinson 's Disease . Evidence severe depression ( score &gt; 10 Quick Inventory Depressive Symptomatology Self Rated [ QIDSSR ] ) . Personal and/or familial history significant suicide attempt .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>cognitive impairment</keyword>
	<keyword>movement disorder</keyword>
</DOC>